Latest From Tocagen Inc.
The firm’s stock crashed on news that its Toca 511/Toca FC regimen did not show an overall survival benefit or meet any secondary endpoints in a Phase III study in recurrent high-grade glioma.
With an average return of 33.2% in 2017, the number of biopharma IPOs that launched last year rose to 42 after falling to 30 in 2016 compared with 62 in 2015. Following a rough fourth quarter for biopharma stocks, will the IPO momentum continue in 2018?
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
There have been 29 IPOs in the US through the third quarter of 2017 with an average return of 35.2%, including three offerings on the same day – Deciphera, Nightstar and NuCana – near the end of September.
- Gene Therapy, Cell Therapy
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Tocagen Inc.
- Senior Management
Martin Duvall, CEO
Mark G Foletta, EVP, CFO
Lori Kunkel, MD, Acting CMO
Nicholas A Boyle, PhD, VP, Bus. Dev. & Mktg.
Fairooz Kabbinavar, SVP, Clinical Dev.
- Contact Info
Phone: (858) 412-8400
4242 Campus Point Ct.
San Diego, CA 82121
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.